Physician profile
Railet Barbara Rodriguez
NPI 1104374164
$14,081.99
in general payments reported to CMS, 2019-2025
56 companies · $5,760 in 2025
The $5,760 reported for 2025 was more than what 99% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $40.06 · 2022: $160 · 2023: $3,567 · 2024: $4,555 · 2025: $5,760.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Education: $17.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,863.73 |
| Education | $17.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,121.75 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $1,066.27 | 2023-2025 | Austedo Xr, Austedo Xr, Austedo |
| Neurocrine Biosciences, INC. | $998.77 | 2023-2025 | Ingrezza, Ongentys |
| Acadia Pharmaceuticals INC | $850.29 | 2023-2025 | Nuplazid, Daybue |
| Ucb, INC. | $746.09 | 2023-2025 | Nayzilam, Rystiggo, Briviact |
| Eisai INC. | $662.67 | 2023-2025 | |
| Pfizer INC. | $630.63 | 2024-2025 | |
| Amneal Pharmaceuticals LLC | $617.40 | 2023-2025 | Crexont, Ongentys, Rytary |
| Alexion Pharmaceuticals, INC. | $530.16 | 2023-2025 | Ultomiris |
| Lilly USA, LLC | $523.44 | 2022-2025 | Kisunla, Amyvid, Emgality |
| Biogen, INC. | $476.16 | 2023-2025 | Vumerity, Leqembi, Avonex |
| Otsuka America Pharmaceutical, INC. | $424.74 | 2023-2025 | Rexulti, Nuedexta |
| Genentech USA, INC. | $412.18 | 2023-2024 | Ocrevus, Evrysdi, Boniva |
| Lundbeck LLC | $365.73 | 2023-2025 | Vyepti, Rexulti |
| Argenx US, INC. | $239.80 | 2025 | Vyvgart, Vyvgart Hytrulo |
Show all 56 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $202.29 | 2023 | Adlarity |
| Celgene Corporation | $195.22 | 2024-2025 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $194.73 | 2023-2025 | Hyqvia, Gammagard |
| Merz Pharmaceuticals, LLC | $193.73 | 2024-2025 | Xeomin, Inbrija |
| Scilex Pharmaceuticals INC. | $190.15 | 2023-2024 | Ztlido |
| Novartis Pharmaceuticals Corporation | $189.18 | 2021-2025 | |
| Kyowa Kirin, INC. | $186.41 | 2023-2024 | Nourianz |
| Axsome Therapeutics, INC. | $152.52 | 2025 | Symbravo |
| Abbott Laboratories | $151.12 | 2023 | Infinity |
| Emd Serono, INC. | $150.18 | 2023-2024 | Mavenclad |
| Tanabe Pharma America, INC. | $132.86 | 2024-2025 | Radicava |
| Csl Behring | $117.36 | 2023-2024 | Hizentra |
| Banner Life Sciences, LLC | $115.34 | 2023 | |
| Supernus Pharmaceuticals, INC. | $110.61 | 2025 | Qelbree |
| Mallinckrodt Hospital Products INC. | $110.52 | 2023-2024 | Acthar |
| Mdd US Operations, LLC | $105.50 | 2025 | Gocovri |
| Horizon Therapeutics Plc | $91.67 | 2023 | Uplizna |
| Ge Healthcare | $74.78 | 2025 | |
| Impel Pharmaceuticals LLC | $57.18 | 2025 | Trudhesa |
| Revance Therapeutics, INC. | $55.53 | 2024-2025 | Daxxify |
| Medtronic, INC. | $49.40 | 2024-2025 | Percept Pc Brainsense |
| C2n Diagnostics, LLC | $47.00 | 2025 | Precivityad2 |
| Microtransponder, INC. | $43.13 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $39.68 | 2021-2022 | |
| Averitas Pharma INC. | $39.22 | 2023 | Qutenza |
| E.R. Squibb & Sons, L.L.C. | $39.07 | 2023 | Zeposia |
| Merck Sharp & Dohme LLC | $38.52 | 2022 | |
| Glaxosmithkline, LLC. | $37.96 | 2021-2022 | |
| Novo Nordisk INC | $32.67 | 2023 | Rybelsus, Ozempic |
| Genzyme Corporation | $32.27 | 2023 | |
| Grifols USA, LLC | $31.79 | 2023 | Gamunex-C |
| Catalyst Pharmaceuticals, INC. | $26.94 | 2023 | Fycompa |
| Boston Scientific Corporation | $26.77 | 2024 | Lux-Dx Insertable Cardiac Monitor |
| Upsher-Smith Laboratories LLC | $24.26 | 2023 | |
| Amgen INC. | $23.03 | 2025 | Uplizna |
| Sk Life Science, INC. | $22.00 | 2024 | |
| Allergan, INC. | $21.10 | 2022 | |
| Janssen Pharmaceuticals, INC | $17.90 | 2025 | |
| Azurity Pharmaceuticals, INC. | $16.88 | 2025 | Horizant |
| Janssen Biotech, INC. | $15.85 | 2025 | |
| Sumitomo Pharma America, INC. | $13.59 | 2023 | Aptiom |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Railet Rodriguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.